Please read these articles
http://boards.fool.co.uk/Message.asp?mid=7842473

http://www.advfn.com/cmn/fbb/thread.php3?id=3982666

http://www.medisys-group.com/Prelims_5_061202-1.pdf'

http://www.safetysyringesplus.com/info.htm

This has massive potential from products other than FUTURA which if it takes off will be the iceing on the cake.Let me give you the highlights from this Mays interims;

Financial Highlights

Financial performance improved significantly:

* Turnover increased by 9% to #20.1 million (2002: #18.4 million)

* Product sales increased by 25% on a constant US dollar exchange rate basis

* Earnings before interest, tax, depreciation and amortisation was #0.3
million (2002: EBITDA loss of #7.0 million, before exceptional items, as
restated)

* Gross margin 37% (2002: 33%)

* Selling, distribution and administration costs reduced to #4.8 million
(2002: #7.4 million before exceptional items)

* Profit before amortisation and research and development expenditure
#2.6 million (2002: loss of #0.8 million before exceptional items)

* Research and development expenditure #3.0 million (2002: #7.1 million,
as restated)

* Operating loss #1.3 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss before tax #1.6 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss per share 0.58p (2002: 2.58p, before exceptional items, as
restated)

Product Highlights

* Sales of existing products in line with expectations

- Sales of Assure range increased to #6.9 million (2002: #5.6 million)

- QuickTek sales to mail order market segment #2.6 million

- Sales of Futura Safety Scalpel #1.0 million in period

- Sales of Advance system #0.5 million in period

* Futura Safety Syringe and Flight disposable blood glucose monitoring
system remain on track for mid-2003 market launch

* Development of Spear capillary fill bio-sensor strip proceeding to
schedule.

Pretty impressive eh !!

Now since this we have had;

FDA approval for Hypogaurd

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=4778825&symbol=LSE%3AMDY

Futura passing final quality tests with Smiths

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5023328&symbol=LSE%3AMDY

A partnership with Walmart for Flight

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5194692&symbol=LSE%3AMDY

Launch of Spear

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5250424&symbol=LSE%3AMDY

Medisys "buy"

Monday, September 29, 2003 8:28:27 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) Analyst I Broadhurst of Dryden Financial issues a "buy" rating on Medisys (MDY.L).

2003 New Ratings

Now this looks to me a company growing rapidly.The more I look into MDY the more confident I become of the potential rewards.These will not be instantaneous but will come over a period of time.Look at the turnaround in those figures posted above.Now that was in a recession.

http://www.charles-stanley.co.uk/content/SMI_oct03.pdf (see page 4)

http://www.research.reuters.co.uk/Research/Earnings.asp?ticker=MDY.L&country=GB&mxid=100068815&companyName=MEDISYS+PLC&sym=RE
VERY IMPORTANT MESSAGE TO ALL BUYERS/HOLDERS - PLEASE LISTEN

http://www.wallstreetreporter.com/profiles/Medisys.html

Moneyman
30P and the rest

Well it's started its move today.Some very large buying towards the close so expect a quick move up in the morning.

SHARE WHISPER:

MEDISYS was given a 1.5p shot in the arm to 21p yesterday on rumours of a full scale commercial launch of its Futura safety syringe through marketing partner Smiths Group.

Analysts were expecting the launch, which will trigger a significant payment, by the end of the year

This has massive potential from products other than FUTURA which as I said if it takes off will be the iceing on the cake.Your comment regarding the fact the syringes sell for 20-30c each is a little stupid.That is the market price.It is like saying you wont make alot of money selling baked beans.These products are sold in massive quantities.Let me give you the highlights from the Mays interims;

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=4747863&symbol=LSE%3AMDY


RNS Number:3564L
Medisys PLC
21 May 2003



Embargoed until 0700 21 May 2003

Medisys PLC
("Medisys" or "the Group")

Unaudited Interim Results for the Six Months Ended 31 March 2003

Medisys PLC, the medical safety and diagnostics group, today announces its
results for the six months ended 31 March 2003.

Financial Highlights

Financial performance improved significantly:

* Turnover increased by 9% to #20.1 million (2002: #18.4 million)

* Product sales increased by 25% on a constant US dollar exchange rate basis

* Earnings before interest, tax, depreciation and amortisation was #0.3
million (2002: EBITDA loss of #7.0 million, before exceptional items, as
restated)

* Gross margin 37% (2002: 33%)

* Selling, distribution and administration costs reduced to #4.8 million
(2002: #7.4 million before exceptional items)

* Profit before amortisation and research and development expenditure
#2.6 million (2002: loss of #0.8 million before exceptional items)

* Research and development expenditure #3.0 million (2002: #7.1 million,
as restated)

* Operating loss #1.3 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss before tax #1.6 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss per share 0.58p (2002: 2.58p, before exceptional items, as
restated)

Product Highlights

* Sales of existing products in line with expectations

- Sales of Assure range increased to #6.9 million (2002: #5.6 million)

- QuickTek sales to mail order market segment #2.6 million

- Sales of Futura Safety Scalpel #1.0 million in period

- Sales of Advance system #0.5 million in period

* Futura Safety Syringe and Flight disposable blood glucose monitoring
system remain on track for mid-2003 market launch

* Development of Spear capillary fill bio-sensor strip proceeding to
schedule.

Pretty impressive eh !!

Now since this we have had;

FDA approval for Hypogaurd

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=4778825&symbol=LSE%3AMDY

Futura passing final quality tests with Smiths

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5023328&symbol=LSE%3AMDY

A partnership with Walmart for Flight

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5194692&symbol=LSE%3AMDY

Launch of Spear

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5250424&symbol=LSE%3AMDY

Now this looks to me a company growing rapidly.The more I look into MDY the more confident I become of the potential rewards.These will not be instantaneous but will come over a period of time.Look at the turnaround in those figures posted above.Now that was in a recession.

You can continue to say what ever you feel about MDY but the facts are here in black and white.

A must read article

http://www.medisys-group.com/Prelims_5_061202-1.pdf

Interesting

Share Bear
Group Captain
Member # 3542
posted 21 September 2003 20:42
--------------------------------------------------------------------------------
I have traced back all the trades for the last 3 weeks (ADVFN doesn't store data any further back!) in MDY & AHT and would appreciate comments on my findings:
MEDISYS:

w/c 1/9/03: MMs bought more stock than they sold every single day of the week. At the end of the week they had accumulated more than 6 million shares!

w/c 8/9/03: By Wednesday, MMs had reduced their surplus by 2 million shares. Then they dropped the price and bought the shares back again (making a handsome profit), finishing the week with >6 million shares in MDY.

w/c 15/9/03: Mon-Wed, MMs accumulated even more stock & by close on Wed had accumulated 8 million shares (since 1/9/03).
Thur-Fri, they upped the price and sold off 2 million shares (again making a handsome profit!)

The conclusion I draw from this is they're expecting some good news from MDY and hence a huge demand for MDY shares & presumably we can expect a price rise so that the MMs can flog their

Old research note but a very interesting read.

http://www.mis-limited.co.uk/BBIC/review/med%2015-11-01.htm

Not looking good for the morning.

http://news.independent.co.uk/business/news/story.jsp?story=446798

Load of the preverbial my friend.

Screaming buy at 15p

Hold on to your hats guys.Comments from analyst at Nomura in today's Telegraph would suggest that MDY "are a definite buy at this level" i.e.15p.I've bought in lower again today and look forward to an early announcement on Smith's replacement as MDY's distribution agent.

MDY has taken a big drop again today. Has it bottomed out yet. And at what price will it rise to when it dos start to go again. I don't know much about this company apart from recent news with Smiths

scot please have a read here

http://www.advfn.com/cmn/fbb/thread.php3?id=3982666

Also something to think about....

Would the FDA have approved FUTURA if it didn't work ?

Monday, September 29, 2003 7:50:25 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) - Analysts at Dryden Financial issue a "buy" rating on the Smiths Group (SMIN).

In a research note published this morning, the analysts mention that although the company had planned to promote the Medisys safety syringe in the US market, the actual customer performance results belied the test trials. Despite the acrimonious parting of ways, neither Smiths nor Medisys stands to lose, the analysts say. Dryden Financial believes that both companies have bright prospects.

2003 New Ratings

Medisys "buy"

Monday, September 29, 2003 8:28:27 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) Analyst I Broadhurst of Dryden Financial issues a "buy" rating on Medisys (MDY.L).

2003 New Ratings

Looks terribly oversold;

Agree MM and hope so!....Dipped my toe in at the bell...22k @ 13.94p and agree cerainly not a one tool company.:)
Definatly room for plenty of upturn and looks way oversold after the Smith's rumble......though always difficult to call the bottom....lets give her some time and see what Santa brings.
Regards
C

Cara wish you good luck.The rally today was very unexpected so i wonder what started it.

Well MM "value" comes to mind,but as stated earlier always impossible to call the bottom of the graph...and prepared to give it time comfortable in the knowledge that it does look oversold.But mainly because I feel that the Smiths issue has blinkered many and an example of this is the deal with Wal-Mart announced recently,about the blood glucose monitoring system...text below for potential buyers...


LONDON (AFX) - Shares in Medisys moved higher after news that the company has signed up US retailing giant Wal-Mart Stores Inc as the partner for the launch of its 'Flight' blood glucose monitoring system.

The group said Wal-Mart will introduce the system at the annual meeting of the American Association of Diabetes Educators in Salt Lake City on Aug 6.



Certainly they do not come bigger than Wal-Mart in retailing and whist I expect a few rallies feel this offers great value and the message seems to have got accross in the last 20 mins.

Regards..
C

ps nice spread as well for a recovery stock...

Think we could see a further rally on Monday opening.

See page 4

http://www.charles-stanley.co.uk/content/SMI_oct03.pdf

Updated header.

Very important.Please listen.

http://www.wallstreetreporter.com/profiles/Medisys.html

hope i very much that your faith in this company will win me over has i have been very disapointed so far????????????

Had a long hard think about a few comments made on this thread and wanted to post a response,

Someone on ADVFN mentioned that Becktons have captured the US market. Is this because they were the first to address the needlestick problem and everyone jumped in ? My thought is probably yes.

Now if there was not an alternative ,bar NMT, but that alternative was higher in price do you change ? NO

Now enter MDY with a comparable if not superior product. You evaluate. You accept and then you look at the price. Hey it's less expensive !

OK we know here in the UK that the NHS is looking at every way to cut back on expenditure and let's presume that it is the same in the US.

Now you have a company offering a comparable or superior product at a discount to what you are presently purchasing at ! What do you do ?

Now on a adifferent subject it is a well known fact that some investment companies will actually short a share to drive the price down and also the weeeker holders ! Is this what has been happening to MDY ?

There is also other market manipulation going on in different area's. As an example it is pure supposition that the MDY sales force will not be able to cope with sales of the Futura syringe so the analysts get worried. Hang on they never forcast that sales of the syringe would have any effect until 2006 ! Now MDY are saying sales will commence Q2 Fy2004 ! So they are taking not effect 2006 sales in 2003 and not looking at the facts on offer. Interesting.

Now take the Walmart deal. No one has really commented that the true sales generated from this will be realised next year. Everyone is interested in the Syringe which will not impact sales until 2006 but is going to be sold in 2004 !

Does it not sound that something is a little wrong here ?

My thoughts but IMO a BUY at these levels for the Future !!!!

well OK so it's Oversold? (opinion here) -Really?
Is the dividend so good that people are prepared to wait for the icing (if it ever comes). Let's not forget that a safety product must work every time - there really is no room for failure - and so why has the needle not been delivered - it can't be the tube, or the needle nor can it be the design of the plunger - all easy pieces to make - It is the retractable bit (silly me!!)- that's the difficulty and the time just keeps on rolling.
Had we listened to the company; the World would be awash this time last year - so did Smiths really expose a truth?
If the answer is yes then all the above sits well with the Smiths opinion - the product isn't going to happen just yet - and maybe not at all - don't think of this as the icing - it could be the Downfall = and who wants to be holding that butt-ugly baby when it's exposed to the world - in the heart of "I'll sue you Baby" culture?

As a past and (lesser now) holder MDY does seem to have a goodly Range of products - but if were the top marketeer I'd be wary of wrecking the status quo - like boring a hole in your life-boat ...to keep the inside dry (until required for use, etc.).
The current situation could be make or break for MDY - if Futura isn't launched, another new product can come along and keep the price sub-20p IMHO, maybe more . If the needle is marketed, the price will double with fanfare and noise ( this share was over 1 when Futura was the future!). -
But if there is a problem, delays in manufacture, a faulty batch (even), a law-suit against them -the price will once again test sub-10p ( didn't they get to 4p?)- and all those who buy-in near 20p will see their investment shreaded - so what's the alternative?

Watch and wait:
Hope the needle is quietly forgotten - or sell it to an American manufacturer on a Royalty basis - income stream for no risk.
A new product will come soon enough, without the baggage of a distressed mistress (wash my mouth) and happy times will be restored and maybe, just maybe there will be a dividend before this decade draws to a close. If there is any hint of a "fund-raising" forget it!
My advice to MDY is: Drop the US market with the needle - maybe a home-market until production is easy - but let's squash the idea that there is a bonansa "over there".

Got to agree with you hangon!!! Wait for something positive> The medisys story with the futura syring reminds of the pen in space story, The Americans spent $15 million dollars inventing a a pen that would work in space, VERY CLEVER you would say! The Russians solved this problem aswell they used a pencil. Will buy back in when i hear something not just speculation and ramping by moneyman

Interesting.

Is only MDY open to a "faulty batch" or "another new product to come along" syndrome?

How on earth would you ever invest in any company on the stockmarket if this is what you base everything on?

The diagnostics side of the business has crept up on its competitors and analysts alike, so much so that the days of 4p (barring a cure for type2 diabetes)are long gone.

Futura has a clearly defined market that now, for the very first time, is being actively promoted by the US Government, health care workers, insurers and the unions.Legislation is in place and spreading from state to state but now more rigorousley enforced, regarding the reduction of needlestick injuries.

The syringe works and is proven to work.Some "End user" resistance that will be solved by training.

Will the hospitals etc consent to this.?
Well given that say in 1 hour you have a shift of nurses paid overtime to learn to use a product that MDY management said in the recent results will "be substancialy cheaper" i believe, on an economics front alone,it stand as good a chance as some but far better than most.

Pheonix41

I was suggesting that MDY drop Futura in the USA (unless they can hive it off for a royalty) as THEY will develop another product, in good time, I'm sure they are not idle.[ i.e. Something different.].....Perhaps this was not clear?

As to your comments re Amrican Government - are you sure? The legislation has been in place for some time "honored in the breach" and the largest supplier (of syringes) has an effective answer to needle-stick, even if it doesn't satisfy MDY investors. (Heath and Robinson spring to mind)

I doubt the "substantially cheaper". Why would something more complex ( more components) be cheaper? I think MDY are trying to beat the existing product-pricing and I suspect the Market Leader could reduce their price substantially before it hurt, whereas MDY would have to admit defeat if first-year sales were only 20% of projection, say.
If I was the US-market leader, I'd want to blow the foreign competition out of the water. Then I'd raise my price, due to unexpected demand etc. etc.
All IMHO
-so all view have equal weight, maybe more.

bivi I have seen you on here and ADVFN accusing everyone of being a ramper.Now


YOU ARE A DERAMPER

DIVI !!

If reality checks are deramping then i guess it is! As to accusing everyone i doubt that, only you and one other on the medisys thread who have yet to take off their sandwhich boards proclaiming BUY BUY BUY all the time

From the provisional accounts

Geographically
2003 2002

#'000 #'000
----------- -----------
Turnover
United Kingdom 433 1,531
United States 36,741 34,116
Other 1,943 73
----------- -----------
39,117 35,720
=========== ===========

With such a high %age of t/o in the US could well be hit by fall in $ against even if not in terms of supply as accounts state source of supply is similar to turnover which does surprise me - ANY KNOWLEDGE? BUT IN TRANSLATION OF PROFIT TO STERLING.

"Geographical turnover is shown by location from which products and services are
supplied. Geographic turnover by location of customers is not materially
different.

Pug accounts posted Dec 2004 now if the $ rallys the recipricol will also be true !

Ofcourse with Hypogaurd being US orientated they will factor in a % to cover $ depreciation. Now will the $ drop any further or will GW Bush make it rally so that the market rallies and subsequently he is re-elected ?

NEW YORK, Nov 18, 2003 /PRNewswire-FirstCall via Comtex/ -- Last week, Paulson Investment Company, Inc. (Paulson Investment) polled executives at the 26th Annual Westergaard SmallCap Conference regarding their outlook on small-cap markets in 2004. 98 percent of respondents expect growth in small-caps in 2004, with 56 percent anticipating significant growth and 42 percent moderate growth, rather than negative or no growth.

"Our goal for the survey was to identify what the investment community anticipates in small-cap market activity in 2004, including growth in industry segments and investment banking," said Chet Paulson, chairman and founder of Paulson Investment Company.

Industries to watch

When asked what three small-cap sectors they anticipate will be most active in 2004, nearly 70 percent of respondents cited biotechnology, pharmaceuticals, and health care industries. Closely trailing was the Internet content and commerce sector which was selected by 66 percent of respondents and the software, communications, security and energy industries which were each selected by 30 percent of respondents as being the most active.

Nomura Equity Research

Date
12 January 2004
Market capitalisation
48.8m
No. of shares in issue
390.3m
Sector
Biotechnology
Reuters / Bloomberg Ref
MDY.L / MDY LN
3 year share price performance
PRICE REL. TO FTSE TECHMARK MEDISCIENCE - PRICE INDEX
HIGH 25.50 29/7/03, LOW 9.00 9/1/03, LAST 12.50 9/1/04 Source: DATASTREAM
1mth 3mths 12mths
Absolute 4.2 -9.1 38.9
Rel. to FTTMMDS -1.1 -12.7 -9.7

Medisys started 2003 with the promise of the launch of the Futura safety syringe and Flight,
the new diabetes monitor. Despite the fact that neither of these events occurred in 2003,
the stock has ended the year about 40% above where it started. The main reason for this, in
our view, is that investors have begun to accept that the companys diabetes-monitoring
business is performing well. Our analysis suggests that, even if the company does not
launch Flight or the syringe in 2004, it still has the legs to get to profitability. We believe a
good outcome for 2004 would be the successful launch of Flight in Q1-04 through Wal-Mart
and a self-launch of the Futura safety syringe (which is not in our model). On this basis, we
believe that news flow and valuation support a Buy recommendation on the stock. On the
other hand, if the company has a problem with the launch of Flight (the syringe is less
relevant as few expect a significant outcome for this product), then the negative news flow
would weigh on the stock. However, as we have quite a low-ball estimate for the products
peak sales (<0.5% market share), the impact on our valuation would be minimal. In such a
case, the weakness in the stock may prompt interest in the company, the continuing
business of which we believe is worth more than the current share price implies.
Recent performance. Delays with the safety syringe and a less-than-amicable divorce
between the company and its marketing partner (Smiths) in September have wiped away a
significant portion of the gains that the stock had registered since the beginning of 2003.
Downside. We believe the biggest issue facing Medisys is its lack of credibility with the
investor community, given the numerous delays to the launches of Flight and the safety
syringe. A further delay to the launch of Flight through Wal-Mart (now expected in Q1-04)
could push the stock down to below 10p.
Upside. We believe that the current valuation does not account for the value of the
underlying diabetes business. If Flight turns out to be a much more significant product than
we are currently assuming, then the stocks undervaluation would become even more
apparent.
Valuation. Assuming Flight achieves sales of 3.9m by 2008 and the syringe is not
launched (our base case), then our DCF suggests a fair value of 23.9p per share (terminal
growth rate of 4% and WACC of 11%). Taking Flight out reduces our fair value to 23.1p.
Thus, on this basis, the stock seems undervalued. In terms of P/E, we also believe the
stock is attractively priced at 6.25x 2005E EPS of 2p. Looking at the companys cash
position, and even assuming no growth in Advance and QuickTek and no new product
launches, the companys working capital facility of 4.8m should be sufficient to see it
through to profitability. Under this scenario, our fair value falls to 14p and the P/E to 8.5x.
12.5p

Hypoguard division
At the last count there were 17m diabetics in the US, 11-12m of whom are treated. The
diabetic population is growing at a net rate of 200-500k per year. The blood glucose
testing market in the US is worth over $2.5bn and continues to grow at over 10% p.a.,
fuelled by the rise in the number of diabetics and the percentage of treated patients. The
US market, by far the largest, is dominated by four major manufacturers (J&J with a 34%
market share, Roche 32%, Bayer 15% and Abbott 8%). The established Hypoguard product
range currently generates the bulk of Medisys sales, which are almost entirely derived from
the US market. This business recorded sales of 35.9m in the year ended 30 September
2003, which represented around 91% of product sales. Medisys has a range of new blood
glucose monitors in Hypoguard of which two (QuickTek and Advance) were launched in
2002. The next product due for launch is Flight, which was expected to be launched by
mid-2004, but is not expected in Q1-04. The business model is that of the razor and razor
blade. Medisys generally places free meters into the market, with the hope of recouping the
costs through captive sales of blood glucose strips. This is why a delayed launch of a
product often actually ends up benefiting the companys cash flow initially.
There are four major sales channels in the glucose monitoring market. The mail order
segment (20% of dollar sales) is dominated by Liberty Medical (part of PolyMedica), with a
70% market share. The retail category, dominated by the four big players, currently
accounts for 60-65% of the market by dollar value. About 5-10% of the market is in the
long-term care (LTC) segment (nursing homes), which Medisys dominates with a 37% share
in dollar terms, up from 35% in the prior financial year. The remaining 10% of the market is
in the hospital setting. Medisys has recently moved into the mail order segment of the
market via the launch of QuickTek and Advance through GEMCO, the second largest mail
order supplier of diabetes products. Retail, the largest market segment, is where Medisys
has yet to launch a product. Flight is destined for this market. Flights main edge over the
competition is its convenience, as the user does not have to handle individual strips. The
strips are contained in a sealed disposable unit incorporating a meter mechanism by which
it dispenses strips, which we believe is novel enough to convert some consumers.
Futura Medical
The established Futura Medical product range includes retractable scalpels, lancets (used by
diabetics) and kits used in blood analysis (ESR). The majority of the upside interest in this
business, however, lies in the new safety-based products led by the safety scalpel and
syringe. Although the former is already on the market, the company has yet to launch the
syringe, which has been a thorn in its side (and that of its investors) for a long time. The
product was due for launch by mid-2003. However, a series of further delays culminated in
a messy spat between the company and its partner (Smiths), which parted ways in
September 2003. Medisys, which has maintained all along that the product has been ready
for launch for several months, is now aiming to launch the syringe through its own 40-
person sales force into the long-term care market directly. This is expected some time in
Q2-2004. We believe that, despite the variety of delays to this product, if Medisys manages
to find another partner to take on a US-wide hospital launch of the product, then it should
do relatively well given its cost, which is significantly below other passive-activation products.
We have erred on the side of caution and have excluded the product from our model. On
the other hand, the safety scalpel has been selling well, although we are assuming a shortterm
fall-off in sales whilst the company takes over marketing from Smiths. We believe that
the market dynamics have not changed much in the three-or-so years that Medisys has
been trying to get the product to market. The US Occupational Safety and Health
Administration (OSHA) continues to estimate that 5.6 million workers in the healthcare
industry and related occupations are at risk of occupational exposure to bloodborne
pathogens. It is estimated that 600-800,000 needlestick injuries (NSIs) and other similar skin
injuries still occur annually among healthcare workers.

Status On market
Probability: 100%
Partner: GEMCO and
Wal-Mart
Patents: NM
2007E sales m
QuickTek: 11.0
Assure/Supreme: 22.2
Advance: 10.9
Flight: 3.9
Lancets: 9.3
Other: 2.5
2007E total: 61.8m
% of total sales: 90%
Status On
market
Probability: 100%
Partner: None
Patents: NM
2007E sales m
Syringe: 0.0
Lark scalpel: 6.3
Other: 1.6
Total sales: 7.9m
% of total sales: 10%
Source: Nomura estimates

Contact
Sam Fazeli
+44 20 7521 3147
Erling Refsum
+44 20 7521 1417
Nomura, London
Anticipated News flow NPV calculation m
Net debt YE-04 27.8
NPV 139.7
EV 112.0
No. shares (m) 467.8
EV/share (p) 23.9
Q1-04 Launch of Flight (New Tek) through Wal-Mart stores
H1-04 Launch of Futura safety syringe through own sales force
into the US long-term care market
2004 New distribution partners for QuickTek and Advance
Source: Company data and Nomura Source: Nomura estimates
January 2004

Medisys PLC Chief Executive Officer Talks to the Wall Street Transcript

http://biz.yahoo.com/bw/040113/135638_1.html

can anyone help me with regards to medisys plc has i have been out of the country and dont know wants been happening with this stock????????//

llew it dropped after they termianted the distribution agreement with Smiths after derogatory comments from the Smiths CEO.THings are comming back on line and the results were very very good.They will now be marketing the Syringe themselves until a new distribution partner has been found.

Seems to be a consistant buyer of large lumps.

L2 strengthed at the close 2 vs 1

thanks very much happy1?lets hope you are right as i have brought some more of this stock?

10S Gone through 50.Higher lows.If it breaks 200.Well?


Worth a punt.

I certainly think it is.

This is now starting to get interesting again

ANY STOCK THAT TRADES HUGE VOLUME AT HIGHER PRICES SIGNALS THE DISTRIBUTION PHASE."

When there was less volume, the price was lower. Professionals were
accumulating. After the price runs, the volume increases. The professionals bought low and sold high. The amateurs bought high (and will soon enough sell low). In older books about market manipulation and stock promotion, which I've recently studied, the mark-up price referred to THREE times higher than the floor. The floor is the launch pad for the stock. For example, if one looks at the stock price and finds a steady flat line on the stock's chart of around 10p , then that range is the FLOOR. Basically, the mark-up phase can go as high as the market manipulator is capable of taking it. From my observations, a good mark-up should be able to run about five to ten times higher than the floor, with six to seven being common. The market manipulator will do everything in his power to keep you OUT OF THE STOCK until the share price has been marked up by at least two-three times, sometimes resorting to "shaking you out" until after he has accumulated enough shares. Once the mark-up has begun, the stock chart will show you one or more spikes in the volume -- all at much higher prices (marked up by the manipulator, of course).

I think we all have to agree that these market manipulators have a damn sight more information than we do. There is nothing to say that they know maybe of impending news and hence that scenario works. What we have seen is a floor established and people wanting to get their money out as other opportunities come along. This is all well and good and I respect that. Some however are keen to accumulate stock at this level as they know that if the management do actually deliver there will be a very strong and sharp rise in the share price.


ADVFN seems to attract traders wanting a 10-20%+ return on their money in a few days. It does not, to some extent, attract investors who are prepared to lock away their shares for a year or two and hopefully reap much better rewards. Go back to the likes of YOO,AHT or CS. and think what mountain of cash you would be sitting on now had you bought and held !

Everyone slags certain stocks off and deservedly MDY has attracted alot of attention due to the recent departure from Smiths.Time is moving closer to the timescales discussed by the MDY management and it is now time to see if they can actually deliver on their promises this time round.

Nomura have given fair value at 20p without Flight or Futura. Now I am quite happy to sit this one out and wait for the long awaited iceing on the cake wether it is delivered in a month or three as I know when we get it we will all be very very happy investors.

Very interesting development on BBC website.Could hold serious potential for MDY.

Very interesting development on BBC website.Could hold serious potential for MDY.
http://news.bbc.co.uk/1/hi/health/3505777.stm

MDY had big sells today can anyone let me know why?has i have not heard anything for a while?????????

pc4900074200 - 26 Feb'04 - 17:32 - 3768 of 3770


Just reading the 2003 Annual reports & accounts.
On page 42 I see that Medisys and Smiths have
agreed to meet and a forum is provisionally set
for March. They will attempt to resolve their claims.

More good news on the way!!

pc

Interesting !!!

This share is an absolute disaster area, I sold my holding last April at 13.87, and look at the price now! " More good news on the way" what are you talking about Happy? Another 12 months waiting for something positive to happen?

Suggest you read the last set of results in more detail then !

1.EBITDA POSITIVE

2.LAUNCH OF FLIGHT TO WALMART

3.LAUNCH OF FUTURA SYRINGE

The price represents the current sentiment which when it changes will be relected.

Medisys is it on the way up on this news:-Medisys, Smiths confirm termination of Futura Safety Syringe distribution deal
AFX


LONDON (AFX) - Medisys PLC and Smiths Group PLC said their dispute concerning distribution of the Futura Safety Syringe has been resolved to the satisfaction of both parties and the Distributorship Agreement between them has been terminated.

Medisys confirms that it continues to market its Futura Safety Syringe product in the US and other markets.

newsdesk@afxnews.com

slm/

OR IS IT ON THE WAY DOWN ON THIS NEWS

Medisys says Hypoguard, 3 others named in complaint for patent infringement
AFX


LONDON (AFX) - Medisys PLC said Hypoguard, its diagnostics division, has been named as one of four defendants in a complaint for patent infringement made by Roche Diagnostics Corp in the US.

The other named defendants are Apex Biotechnology Corp, Medline Industries, Inc and Home Diagnostics Inc.

The complaint, in the Indianapolis Division of the US District Court, alleges that the use and sale of the Assure family of blood glucose monitoring products infringe two patents owned by Roche.

The Assure products are made and supplied to Hypoguard by Apex under a supply and distribution agreement. This agreement includes an indemnity, given by Apex to Hypoguard, for liability arising from the Assure products infringing the intellectual property of a third party, Medisys said. Apex confirmed that it will stand behind such indemnity in relation to Roche's complaint, Medisys added.

Hypoguard said it is investigating the validity of the patents and will respond to the complaint once it has completed its probe.

newsdesk@afxnews.com

jc

No matter which one you choose, today saw a 7.3% rise with trades of 18 or so million 12.5million buys to 8.2 million sells. This company would appear to be in the wars and not only needs an injection but some protective headgear and body armour to avoid being too hurt from the head,body, heady blows. One thing after another seems to halt its recouperation. It would seem that it is a cheap stock at this time, just a little get well note from the injured party would let us know that it is on the road to recovery and would be well appreciated by its 'family' of shareholders. Good luck DYOR.

Happy get a life and put your money in to something else.

Scottie SIT there's a good BOY !

SOme people dont fully understand the potential returns on offer here !

Scottie, if you're not into this, why waste your time (and ours) posting useless statements?

This is why people will invest in MDY !

Jenniferzz - 6 Mar'04 - 10:26 - 5093 of 5096


LONDON (AFX) - Tadpole Technology PLC year to September 30 2003
Sales on continuing ops - 3.57 mln stg vs 1.84 mln
Pretax loss - 9.57 mln stg vs loss 11.14 mln
Loss per share - 4.3 pence vs LPS 5.7

TAD MKT CAP 54 Million, sales 3.57 million, 9.57 million loss

LONDON (AFX) - Medisys PLC year to September 30 2003
Sales - 39.59 mln stg vs 35.72 mln
Pretax loss before exceptionals - 2.50 mln stg vs loss 19.58 mln
Pretax profit before exceptionals and goodwill - 4.1 mln stg vs loss 2.5mln
Pretax loss - 5.68 mln stg vs loss 32.99 mln
Operating loss before exceptional - 1.99 mln stg vs loss 19.52 mln
Operating loss - 5.51 mln stg vs loss 31.82 mln
EBITDA - 1.1 mln stg vs loss 14.8 mln
Loss per share before exceptionals - 0.97 pence vs LPS 5.37
Loss per share - 1.78 pence vs LPS 8.85

MDY MKT CAP 42 Million, sales 39.59 million, EBITDA positive

Compare TAD or a mulititude of others with MDY and MDY is far better
value and any growth story scenario is dismissed and should the Queens huskies fart in her lounge at the weekend then this is certain to result in a mark down in the MDY share price. The value of this company will be borne out and a significant higher value or a takeover of the business is inevitable.

According to the last paragraph look for some more new products to boost sales later !!

New Retractable Syringe from Medisys


Pharmacy Today

The UK company Medisys, in an effort to conform to new US laws protecting medical staff from needle-stick accidents, has developed a hypodermic syringe with retractable needle. Medisys' Futura syringes have an automatic retractable needle that retracts into the syringe when the hypodermic plunger is fully depressed. They are expected to be on the market later this year.


Stricter US laws are a reaction to the 800,000 needle-stick injuries that occur annually in the US, all of which have the potential of spreading the human immunodeficiency virus (HIV) or hepatitis. It is increasingly likely that these stricter laws and regulations will be replicated in Japan, Singapore, and other countries.


The retractable technology of the Futura syringe is the core of Medisys' safety development measures, which are exploited in a number of other products. The company also expects to release a safety catheter with a retractable needle mechanism within the next 18 months.

Shipments to Walmart beggining !!

Parlex To Add Greater Value On Computer & Medical Projects

METHUEN, Mass.--(BUSINESS WIRE)--March 3, 2004--Parlex Corporation announced today that two major customers have qualified Parlex to provide additional assembly services on flexible circuits they currently supply. As a major supplier to the inkjet printer market, Parlex will now place surface mount components on many of the products it manufactures. Component attachment will utilize Parlex's patented, lead free adhesive, Polysolder(R). Based on customer projections, this additional scope could add up to $4 million to its computer segment sales over the next 12 months. In the medical market, Parlex has been a supplier of glucose monitoring test strips for the past 15 months. Our customer, Hypoguard, the diagnostic division of Medisys PLC, has qualified Parlex to produce a fully integrated glucose monitoring system with 100 pre-calibrated test strips in a disposable pre-loaded meter. Parlex anticipates that this transition will more than double the unit value of our product. Shipments are scheduled to commence in the next few weeks.


Peter J. Murphy, Parlex President and CEO stated, "It is clear that moving up the value chain should accelerate revenue growth and strengthen relationships with our customers. We believe that our ability to offer the widest range of flexible interconnect products, including value added products, will enhance our position in the marketplace. The Company currently has an added value element on approximately 30% of our business; our goal is to increase this to over 50% by year end."

About Parlex Corporation

Parlex Corporation is a world leader in the design and manufacture of flexible interconnect products. Parlex produces custom flexible circuits and laminated cables utilizing proprietary processes and patented technologies, which are designed to satisfy the unique requirements of a wide range of customers. Its manufacturing facilities are located in the United States, China, Mexico and the United Kingdom.

The foregoing contains certain forward-looking statements. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of various factors beyond its control, including economic conditions in the electronics industry, particularly in the principal industry sectors served by the Company, changes in customer requirements and in the volume of sales to principal customers, competition and technological change. For a detailed discussion of these and other cautionary statements, please refer to Parlex's filings with the Securities and Exchange Commission.

A great post worth sharing !

Author german bite View Profile | Add to favourites | Ignore
Date posted today 12:26
Classification Comment
Subject: My Reasons
Opinion Strong BUY
Recommendations This message has been recommended 10 times, including by you
Message


********************

Those of us that are involved with the stock market know that is not an exact science in so far as valuations v's the share price of a quoted company are concerned. Indeed we all know of companies that over the years have been OVERVALUED or UNDERVALUED in relation to the company/underlyeing business a direct opposite to what the share price (market cap) was saying at the time.

I start off by saying that some of the "previous" managements decisions/deals/rational "appear" to have been, to put it mildly, very poor, but I HONESTLY BELIEVE those days are behind us and the company under the CEO David Conn, is now in good hands.

So lets have a look at MEDISYS basic core business which it SHOULD be VALUED on today:

TURNOVER: 2001 2002 2003

20.9mm 35.7m 39.1m

All well and good but what about costs such as Admin,Sales and Distribution?

SALES and DISTRIBUTION COSTS:

27% of REVENUE 2001 20% of REVENUE 2002 12% of REVENUE 2003

ADMIN COSTS:

21% of REVENUE 2001 18% of REVENUE 2002 13% of REVENUE 2003

RESEARCH and DEVELOPEMENT:

23% of REVENUE 2001 38% of REVENUE 2002 12% of REVENUE 2003

NOTE:As you can see a MASSIVE amount of money was spent on R and D (2002)mainly due to getting the FUTURA SAFETY SYRING and NEWTEK (Wal Mart)monitor ready.Now that they are ready for market less R and D expenditure is incured as you can see by the fall in 2003!
____________________

Worth noting at this point that Diabetes Monitors are "sold at a loss" by all companies and the profit is gained from subsequent sales of the "test strips".So if a NEW monitor is brought to market,innitialy it hits costs for little return.HOWEVER the new monitor we have invented and are bringing to market via WAL MART is an ALL in ONE that has test strips built in so will be sold with an IN BUILT PROFIT MARGIN at point of sale.

______________________

Were are our markets:?

TURNOVER:

UK 2.944m 2001 1.53m 2002 0.433k 2003

US 26.49m 2001 34.11m 2002 36.74 2003.

OTHER 0.464k 2001 0.730k 2002 1.943m 2004.

From the above I looked at the LOSS on the UK business of 13.37m in 2002 and a LOSS of 3.451m in 2003 to ALLOW for the possibility that we will, at some point, become just a USA company either quoted on the NasdaQ or simply bought out by a USA based company.

CLASS of BUSINESS TURNOVER:

DIAGNOSTICS : 23.17m in 2002 31.12m in 2003.

HEALTH SAFETY PRODUCTS 4.027m in 2002 3.86m 2003.

This gives us our "core" market.I would like to point out at this stage the reasons I am not "worried to death" about ROCHE.

Medisys have declared they are indemnified by Apex,however we do not know at this stage how "wide"

Make no mistake it is not ideal.From this point we have to make some MASSIVE assumptions and other less so large ones!

Firstly, there has to be MERIT in ROCHES claims.

Secondly they have to prove this.

Thirdly, they have to WIN in a court of law.

So ASSUMING the worst, MEDISYS have to stop selling the ASSURE meters,well we DO HAVE OTHERS but how hard is it to replace a best seller??

This is a run down of MEDISYS previous FLAGSHIP betselling monitor the SUPREME that is casually and very successfully being replaced by our other monitors.

SALES of SUPREME:

2001 10.5m 2002 7.6m 2003 4.2m

My point being, if MEDISYS can REPLACE the above monitor so successfully in such a relatively "short" time span when there is no RUSH, imagine what they could do if they needed to "transfer" old ASSURE users over to NEWTEK,QUICKTEK or ADVANCE meters!

To some up the company under David Conn have cleaned up the books with MASSIVE write offs the put a line under past "management mistakes"

They have REDUCED Sales and Distribution costs:

They have REDUCED Administration costs:

They have REDUCED R + D costs, yet still keep a healthy spend of approx (on my expected 2004 numbers) of around 11% of TURNOVER,to show that more NEW PRODUCTS are in the pipeline, after all this is the FUTURE REVENUE.

They have INCREASED Turnover.

They have increased Gross Profit

They HAVE IMHO already taken us (as results will prove interims March 2004)into MAIDEN profit.

This is without ONE PENNY of revenue from either the FUTURA SAFETY SYRINGE or NEWTEK.
**************

I FULLY take on board the markets at this moment in time do not like MEDISYS or its past management mistakes or unforfilled promises but there WILL come a point were the UNDERLYING real tangible proven (in the accounts) VALUE and WORTH of this company will shine like a beacon for anyone that cares to look.

If the institutions choose to continue to ignore us and refuse to walk toward the light, then there is a VERY REAL chance IMHO of EITHER a TAKE OVER, MBO or going private or as mentioned before QUITING the UK altogether for the US markets who are more aquainted with our HYPOGUARD arm/brand anyway.

How base market place is growing all over the world.Our REACH will grow along with Wal Mart (and other partnerships we "actively seek")and barring an overnight "cure" for diabetes (equal too petrol not being needed overnight, so Shell better watch out!)no matter what happens to an extent to acconomies,DIABETES is growing and the need for our products grows by the day too.

What ever happens,I HONESTLY believe that my INVESTMENT in this company will REPAY me handsomely in the FUTURE for my faith and patience.


GB (Lisa279)

Medisys shares jump on syringe launch
Mon 22 March, 2004 08:56
RELATED REPORTS
MDY.L Profile Report
Business description, 3yr and interim financials, key stats/ratios & analysis.
| 12 pages | 10 | Details


LONDON (Reuters) - Shares in Medisys have leapt as much as 26 percent after the medical devices firm said it had launched its long-delayed Futura Safety Syringe in the United States and received its first big order.

At 8:35 a.m. on Monday, the shares MDY.L were up 23.8 percent at 13 pence, off an early high of 13-1/4p and valuing Medisys at about 53 million pounds.

The Futura Safety Syringe, whose needle retracts to stop hospital staff from pricking themselves, was originally planned for launch more than two years ago, but was dogged by testing delays and an argument between Medisys and the firm's original distribution partner, Smiths Group SMIN.L .

Medisys sacked Smiths in September after that firm's chief executive, Keith Butler-Wheelhouse, was quoted in a newspaper as saying he had "almost given up" on the Futura Safety Syringe.

Medisys said it had launched the syringe through its own 40 person sales and marketing team and won its first big order from an unnamed medical products distributor in the United States.

It also said it was continuing to explore a potential major distribution partnership.

Bet you wish you hadn't sold out now chickens!!!

Onwards and upwards with futura leading the way.

LOL !

I'm am actually now getting very excited by MDY ! Why ?

Well when the stock market was down heavily the share was trading as high as 26p.News of the split with Smiths and the patent problem have driven the price down 50% !

The Futura issue which everyone has been waiting for has now been resolved and lets just anticipate that the news on the patent front is unfounded.During this downtime we also went EBITDA positive.

Now those factors alone should really see us moving back to the recent highs if not higher and with the possibility of additional good news we could all be looking at a very Merry Christmas.

And it helps if you bought more at the depressed prices like I had the kahunas to do!

Roll on 20p, 30p, 40p, etc, etc (ramp away until my eyes bleed!!!!!)

We just need to hear that a major international distribution company has come on board for this to sky rocket IMHO. Then we can wait in anticipation for the full results after all the products are on line and rolling off the shelves! NICE!!!!

AGM this week ?

Thursday Happy1 :)

Gotta be more good news at the AGM. I'm hoping the Smiths debacle did not effect earnings and turnover too much. Did Mdy ever see the cash Smiths owed them for the contract termination?

Roll on tomorrow!

Looking very good today.After a 28% rise we had a bit of profot taking and are now firmly into an upward trend.

RNS Number:9201W
Medisys PLC
25 March 2004



For Immediate Release 25 March 2004


Medisys PLC
("Medisys" or "the Group")


FirstOrder For NewTek Blood Glucose Monitor Received From Wal-Mart


Further to the AGM Statement released earlier today, Medisys announces that it
has now received the first purchase order for its NewTek product from Wal-Mart,
the Group's exclusive USretail partner for the product.


The purchase order was received overnight and will be fulfilled from existing
inventory. It is anticipated that shipping will commence today.


Dave Conn, Chief Executive, commented: "The receipt of our first order from
Wal-Mart is a major milestone for the Group. NewTek is the first ever fully
integrated, disposable blood glucose monitoring system offering a new level of
convenience to the user. We are excited by its prospects as part of Wal-Mart's
well established ReliOn(R) brand, which offers value based products to their
diabetes customer."


- Ends -

Enquiries:


Medisys PLC 020 7563 5200
David Conn, Chief Executive Officer

Michael Barry, Chief Financial Officer

A very robust defence claim to the Roche problem !

Now we are opening up the diabetese market into Europe.Massive new revenue channels !

Moving into Europe today ! The good news just keeps on coming !!!http://www.uk-wire.com/cgi-bin/articles/200404300700111754Y.html

We also have interims comming up and the $ has been strengthening against sterling. This will soon have a re-rating IMO.

Another snippet of news is that NMT have sorted the patent claim with RTI but are now unable to sell in the USA.Who will Roche now use ?

Less competition.Let the good times roll !

Techmark movers: Medisys up, Antisoma down

Fri 30 Apr 2004


LONDON (SHARECAST) - Medisys picked up after it received notification it can put the CE mark to its Advance Micro-draw blood glucose monitoring product which will allow it to market the product within the EU.

The company says it is selling the Advance Micro-draw product by the mail order in the US at present.

"Strategic partnership opportunities with suitable potential European marketing partners are currently being explored with a view to maximising market penetration of the product," it said.

Chart wise looks ripe for a positive breakout.

Thanks to Lisa

Roche's Taq patent held unenforceable for inequitable conduct
[Published: 20 May 2004 Source: Anti-Infective Drug News from Espicom]

Judge Walker of the US District Court in California has ruled that Roche's patent (No. 4,889, 818) covering Taq DNA polyermase is unenforceable due to inequitable conduct. The Judge also dismissed all four of Roche's breach of contract claims and sought additional evidence before making a conclusive ruling relating to the unenforceability of the PCR patents.

This case comprises a series of six intentional and material misrepresentations to the PTO as part of Roche's efforts to procure the patent, including the fabrication of data and experiments. In noting that the misstatements made by the patent applicants were both material and "made with intent to deceive the PTO," Judge Walker ruled that "the equities warrant a conclusion that the patentee has engaged in inequitable conduct . . . and the appropriate remedy is to hold unenforceable the patent obtained by inequitable conduct." The court then dismissed all of Roche's claims related to the Taq patent, rendering it unenforceable against Promega and the public, including the many healthcare institutions and universities using Taq in their research and clinical diagnostics testing.

In addition, the Court concluded that "the inequitable conduct that occurred during the prosecution of the '818 patent bears an immediate and necessary relation" to the Taq DNA polymerase license that Promega had entered into. On that basis, the Court dismissed all four of Roche's breach of contract claims.

************************

Have a great weekend one and all!

Lisa :)

I think in 6 months MDY will be in profit. Then the fireworks start. I am using the dips to add and feel that MDY is really turning itself around but has lost credibility.


A real shame but those that BUY and HOLD will be rewarded in the future.

At sub 10p a bargain not to be missed !

Now starting to recover.

Ideal time to add at this level.

nigel_man - 23 Jun'04 - 10:48 - 13069 of 13073


US Distributor of Futura Safety Syringe - Briggs Corporation?
see catalog entries for Futura 3cc syringes.

http://www.briggscorp.com/e2wItemQuickSearch.aspx?searchText=futura%20safety%20syringe

New distributor of NewTek and Hypoguard range outside of the US - Artic Medical!!!

http://www.amlonline.com/MainSite/html/news.html
http://www.amlonline.com/MainSite/index.html
http://www.amlonline.com/MainSite/html/diabetes_care.html

Confirmation of sales through Walmart

http://www.diabetesnet.com/diabetes_technology/blood_glucose_meters.php

Ingles Manor
Castle Hill Avenue
Folkestone
Kent, CT20 2RD, UK

Tel: +44-1303-850856
Fax: +44-20-7900-2255

info@arcticmedical.co.uk

Updated 19 June 2004



Arctic Medical









Welcome Our goal is to provide you with useful information about our company and the products so that it makes it easier for you to do business with us.

Arctic Medical now has the honour of distributing Hypoguard products for blood glucose measuring and urine analysis outside the US. Please contact us about these products. Hypoguards information sheets can be downloaded through this site.

Product range:

Hypoguards blood glucose meters and strips.
Hypoguards urine strips - clinical and personal use.
The SWELAB blood cell counters - clinics and laboratories.
Bio Products Laboratorys blood plasma products - haemophilia and intensive care.
Palco Laboratories diabetes care products (available online) and enuresis (available online) .
Owen Mumfords erectile dysfunction products (available online).
EasiGRIPs tubular elasticated bandages (available online).
The UASure meter and strips for uric acid (gout) sufferers (available online).
Wisdom of Natures aloe vera skin care products (available online).
Advanced Care Products Heel Care ointment (available online).
Some of these products, as indicated, are available online to individuals through our shop.

Feel free to browse around this site. If you have comments or questions about our products or services, or simply need more information and want to contact us, click on the contact button on any page within this site.

Thank you for visiting and we look forward to serving you.

Note: Not all products are available in all markets. Please contact us.


Shop with Arctic Medical




Advanced Care Products Shop




Information








--------------------------------------------------------------------------------


Comments and suggestions to our Webmaster please.
1999-2004, Arctic Medical Limited, Arctic Medical, Arctic Medical (UK), AML, AML Online.

Here is a risk reward scenario.

MDY is worth a far greater price than it is now. The lowest it has ever been was 4p the highest in the pound area. Why not invest a few bob ? This company is EBITDA positive and is nearly profitable.

It has launched some great new products and is growing. The reason for the share price collapse are three fold;

1.Loss of their major distribution partner.

2.Weakness of the $

3.Patent infringement case with Roche.

Please look at the following as arguements against the above;

1.In the recent interims it states that Futura syringe is being shipped to a major distributor.

2.The US economy, at some stage,will strengthen. After the recent losss associated with the $ the company is hopefully hedging.

3.Read the response from Medisys and also the news regarding the success of Roche in these case.

Also contemplate the following which has not been taken into account with the share price;

1. Walmart deal

2. Futura Syringe launch

3. Possible launch of 1cc and 5cc syringe and catheta.

4. Strengthening of the $

5. Nomura's estimates even after the Roche case.

6. The move to profitability as our CEO said they are expecting substantial growth.

To me these are enough reasons as to take the risk, which we do with any share, and BUY Medisys. People are calling this down to 5p which is 3p from here but the potential upside is in the teens or twenties. Risk reward is always worth taking into account and the reward IMO far outweigh's the risk.Why ??? We know that people will pile in at 5 or 6p just like they did before and drive the price straight back up. On the other hand with good news we could see a 100% gain very very easily.

The question is do you want to sit on the side or not ? Would you like to be on the end of a stock which easily has the potential to double or even treble with the right news ?

There are many which post negative comments regarding MDY but with no facts. Above are the fact both good and bad and the reasons why the price is where it is. Please join the discussion and ask posters why ? and also for factual information to back up their claims !

MDY is and will be a good company. You will see this in the future.

Thankyou



Have a good weekend.

Maybe, Happy1 - but this Co has made promises in the past and that's all history. Their SP has been on the wane as investors left before the whole sorry tale of Futura was wrung dry. They are no-longer a blue-sky company - they are sticking to their knitting and are pretty well stuck in a rut. Last agm the SP was about 14p and now just months later it has halved and lost some more.

Much of their business is in the US and as you observe, the USD is against further profits......so my take is: SP will stay close to these levels until a take-over or a new product is launched. However, there is little chance of that - what is out of character is that they managed to launch the 1st version.

Why don't you ask them about a dividend?
regards

Somthing to think about which did not occur to me....

Why did it take Roche so long to file the patent infringement case ??

Spoiling tactics ?

Bit of excitement today (and slightly yesterday as some were in posession of facts not known to the rest of us - oops!
A further product deal looks likely to be profitable and with little risk - goody. As Happy1 has been saying there is potential - and at these prices little risk. I sold out about the time of the agm (13p?) so today's price looks pretty good value. I'm a buyer today 8p+
Compared with some stocks available at least this is one that is easy to understand. MDY fulfills a market need and it results in repeat sales - that's good enough for me. I sold on the lack of news which traditionally lets prices slip rather a lot. The rise at the agm was Director-buys =window-dressing IMHO.

[ The Roche issue (delay) could be nothing more than large company time-scales as being so busy large companies have less sense of urgency and for all we know may have been trying to negotiate also. I think this is a side-show issue as presented. ]

Breaking News: Medisys wins contract and plans placing
Published: 08:22 Thr 29 July 2004
By Phill Cozens, Stockmarket Correspondent
Email to a friend | Printable Version


Medisys is to supply its Advance Micro-Draw blood glucose monitoring product to Liberty Healthcare, a direct to consumer US mail-order diabetes products supplier.

David Conn, chief executive of Medisys (MDY), said: 'This major new agreement is expected to generate sales of $38 million (21 million) over its first three years and will position Medisys as a key supplier in this rapidly growing market.'


The company plans to raise 5.9 million in share placing and open offer, of which about 3.5 million will be underwritten by Altium Capital.


Trading remains in line with expectations.

Evolution Beeson Gregory 100 Wood Street, London, EC2V 7AN 020 7071 4300
Medisys (MDY) Add (from Reduce)
Mkt cap: 29m Net cash: -9m Product update Price: 7.5p
Mail order agreement and fundraising
The supply agreement with Liberty for the Advance Micro-draw product is
a significant step forward for the mail-order business, but visibility on
other areas remains an issue.
Following on from yesterdays mysterious announcement regarding a
supply agreement for the companys Advance Micro-draw product,
Medisys announcement this morning has shed some light. The agreement is
with Liberty Healthcare Group a significant player in the US mail order
diabetes product supply market (est. 40-50% market share) and Medisys
aims to raise up to 5.9m (net of expenses) to increase its manufacturing
capacity for the product in question.
Of the 5.9m, around 3.2m (net of expenses) has been raised via the placing
(3.5m fully underwritten by Altium Capital, and certain Directors
irrevocably undertaken to subscribe for 0.22m). This is probably sufficient
to cover the capex required for equipment to manufacture Micro-draw; the
remaining 2.7m is thus required to provide additional headroom for
working capital. We gather the contract does not specify a minimum figure
for funds raised, however we do understand the agreement with Liberty is
conditional upon the placing and open offer becoming unconditional in all
respects on or before August 31 2004.
In terms of the contract itself, the agreement with Liberty is for five years,
with no contractual minimum purchase requirement. Medisys expects sales
to be generated over the initial three-year period of $38m (c20.8m). We
anticipate this would see stepped revenues of approximately $10m in the
first year, with the potential for c$12-13m and $15-16m in the second and
third years respectively. In terms of margins, we also anticipate margins to
be lower in the earlier periods, moving from c10% gross margin to c20%+
over the three years.
While we understand that Medisys has commenced supply in anticipation of
the agreement (c$1m sales value of product up to June 2004), we do not
expect the agreement to have a significant beneficial impact in the current
financial year. Indeed, with raised expenditure in the near-term, we
anticipate a slight negative impact on earnings during FY2004, but with the
initial uplift coming through in FY2005.
So does this constitute a turning point for Medisys mail-order business?
While todays announcement demonstrates positive progress, it is unlikely
that the company will be able to replicate an agreement of this significance in
Agreement with Liberty
Minimum proceeds of 3.2m raised
5 year agreement; reasonable
visibility over initial 3 years
No beneficial impact until FY2005
MEDISYS
JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL
6
8
10
12
14
16
18
20
22
24
26
Source: DATASTREAM
29 July 2004
the diabetes/mail-order arena. The agreement has been over a year in the
making, and with c40-50% share of the relevant market Liberty is the
obvious partner of choice. We might also infer that the conditionality of the
agreement upon raising funds for manufacturing capacity reflects the lack of
visibility Medisys management have in their target markets.
The issue of visibility in other areas is also one for consideration: the roll-out
of the NewTek glucose monitoring product in all 3,400 Wal-Mart US
pharmacy outlets by September 2004 is apparently on track, but translating
this to actual units sold is difficult. Sales of the Futura Safety Syringe (c1-2m
in the current year) are also significantly below what we would expect for
the company to see profitability on the product unless there is significant
commercial progress in this area, we believe sales growth of the product will
be challenging.
Todays news then prompts us to upgrade our recommendation from
Reduce to Add but we do so with caution. There continue to be a number
of variables on which the company has limited visibility, notwithstanding
external issues such as dollar weakness.
Dr Mike Mitchell +44 (0)20 7071 4436 mike.mitchell@evbg.com
Year end Sales (m) EBITDA (m)
PTP adj
(m)
EPS (p) PER (x) EV/Sales (x) EV/EBITDA (x) Revised?
09/03A 39.6 1.1 (2.5) (1.0) NEG 1.0 34.8
09/04E 37.5 2.1 (0.7) (0.4) NEG 1.0 16.6 Yes - down
09/04E 47.0 5.6 3.0 0.5 24.6 0.9 6.8 Yes - up
Visibility is the key

There are many other examples but what we have to look at now is the future. If this does take off as the team think it will then this will be the turning stone for MDY ! Why do you think they used the wording"substantial growth" in the recent interims ? This of course was known but few took heed of the information.

Now let's just add to this the following;

1. Walmart exceeds expectations.

2. Futura becomes a massive hit.

3. roche drop the case.

Where is the SP going to be ? Could MDY now,at worst case,drop Assure and switch to Advance ???

The fact that we are now playing with the BIG BOYS who control 40-50% of the market says that MDY are looked upon as a major player in a billion dollar industry.

Now this is only the US we are talking about. What about Europe which MDY have set their sights on ?

People will always buy MDY for a short term gain. Few will buy for the long term potential which is what the company is saying to us.

Look we could easily be worth 60 million + in a few years ! Work out the potential for the share from this level to what it "could be" in say 3 years ! This is the reason why some posters here have a long term view.

Medisys strikes sweet deal with Liberty Healthcare
Published: 18:11 Thr 29 July 2004
By Edward Thornton, Columnist
Email to a friend | Printable Version

Medical technology company Medisys got a lift today after agreeing a five-year contract to supply its Advance Micro-draw specialist glucose monitoring product to Liberty Healthcare Group.

The deal with Liberty, a US mail-order diabetes product supplier, is expected to generate sales of $38 million (20.8 million).


Medisys launched a 5.9 million placing and open offer to fund an increase in production to support the Liberty contract.


Chief executive David Conn said: Developing the mail order channel for our next generation of blood glucose monitoring products is a central part of our growth strategy. We are therefore delighted to have reached this agreement with Liberty, adding that the deal will position Medisys as a key supplier in this rapidly growing market.


Medisys (MDY) shares gained 1.1p to 8.5p, a rise of 15.3%.


This is the latest bit of good news for Medisys, which was hit last year when Smiths pulled out of a joint venture to promote Medisys' needleless Futura safety syringe.


In March the company received its first order from US retail giant Walmart for a disposable, blood glucose monitoring product. This was launched in pharmacy outlets stores under the name NewTek. The company hopes that by the end of the financial year the product should be available in 3,400 Walmart pharmacy outlets in the US.


As part of the fund raising 39.1 million placing shares and 12.9 million open offer shares have been placed with institutional investors on a one for seven basis. Altium Capital has underwritten 3.5 million of the fund raising.


The deal is taking place through Hypoguard, the US subsidiary owned by Medisys, who will initially act as supplier. The product will take on the Hypoguard brand name but will then either be replaced by the Liberty name or co-branded.

2004 Citywire

Comeon people let's look at this deal logically. For no debt on the books Medisys has struck a major deal with the No1 player in the US mail order diabetese market. To achieve the anticipated production they have done a placing which has been part underwritten by a major company which specialise in investing in growth companies http://www.altiumcapital.com/

This deal is anicipated to increase turnover dramatically whilst lowering overheads thus increasing profit margin....all good for the shareholder.

What happened prior was the retail investor sold out driving MDY to a very low share price whilst the likes of the MMs sat on 100Ks of stock and are now entitled to the placing as well.

The company would not IMO have struck this deal if there was any reservations from Liberty. Also Liberty must have shopped around and found the best partner. Now to go over some news that has already taken place but is in no way factored into the share price;

1. Succesful launch of the Futura syringe - we do not know what is currently happening although we do know that an order was placed by a major US distributor.

2. Walmart have confirmed that the Relion is now available and is available now. OK so Walmart had to place an initial stocking order. How many stores do they have ? Mmm could be interesting.

3. We have seen through research that the safety scalple is available through a number of distributors.

4. With Medisys's sales force going DIRECT the profit is not going to the middle man but direct to our company.

5. We have a major diabetese conference comming up where news could/should be released.

There are many other factors to suggest that people buy MDY stock but I think that one of the major issues is going to be the company moving into profitability very soon.

I wish all good luck long or short (burn ;-))

HOW COME ALL THE BUYING TODAY SOME NEWS BEING LEAKED ?

Looks like it may be turning.

Surely it is only rising today on the back of ZIM.

Up again today after the 1M buy. Also did you notice the P trade yesterday.

I can't see this rising in the v.short term - and where are the RNS on the site?

With new models of diabetic monitors and repeat business in the US the only problem is the USD-movement affecting profits. This is short-term and what we see is a company that has (at last) got to grips with reality and concentrated on its core business that is protected in some measure as it's repeated - once a diabetic, always a diabetic.
All at once we should see profits as their syringe R&D is disbanded. That's my hope and I took part in their fund-raising efforts to tide them over. It's a pity that some punters have taken fright because the Blue Sky has been switched off; but this co. is now Real.... Real products and real sales.

Something going on today.

One MM on the offer now.

Something going on today.

As a newcomer, what could be going on?

Rise was based on two facts as far as I can see;

1. Nomura had a large seller who was finally matched today thus eliminating the overhang.

2. Rumour of consolidation in the medical devices industry promting people to consider MDY as a possible takeover target
http://www.sharecast.com/cgi-bin/sharecast/story_list.cgi?title=Market%20Reports&id=0200,0201,0202,0203,0204,0210,0211,0220

When are the full year results going to be announced?.

Well is this the start of the recovery or another false dawn ? All the bad news is hopefully behind the company and the $ is recuperating which will transfer into greater turnover. Could be the time to get in prior to the new European distributor being announced.

Chart says it all ... fill yer boots.

Confirmation and BIG NEWS is about to be released.
Fill your boots indeed!

Facts please not speculation